Skip to main
  1. Stocks
  2. STERIS
  3. Forecast
STE

STERIS (STE) Stock Forecast & Price Target

STERIS (STE) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Steris is well positioned by resilient demand across Healthcare Services, AST, and Life Sciences, with 2Q organic growth of 8.1% and FQ1-27 organic growth of 6.2% showing durable underlying momentum. Margin execution is also strong, as adjusted operating margin reached 24.6% in 2Q and 23.8% in FQ1-27, while EPS beat expectations and management maintained FY26 and FY27 growth guidance, signaling confidence in the runway. Additional upside comes from improving late-quarter demand, backlog strength in healthcare equipment, and the planned Xodus Medical acquisition, which is expected to add growth, margins, and EPS once completed by end of CY26.

Bears say

Steris is exposed to a negative setup because its earnings and valuation depend heavily on procedure volumes, capital equipment spending, and steady global healthcare demand, all of which can weaken if spending slows. The company also faces meaningful external risks from unfavorable tariff policy changes, supply chain disruptions, and inflationary pressures, while its exposure to new FDA regulatory actions adds another layer of uncertainty. Given its concentration in healthcare services and sterilization-related businesses, any disruption to hospital purchasing or biopharma demand could pressure revenue growth, margins, and operating visibility.

STERIS (STE) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.

STERIS (STE) Analyst Forecast & Price Prediction

Get the latest STERIS (STE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STERIS (STE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STERIS (STE) Forecast

Analysts have given STERIS (STE) a Buy based on their latest research and market trends.

According to 4 analysts, STERIS (STE) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $283.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $283.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STERIS (STE)


STERIS (STE) Analyst Forecast & Price Prediction

Get the latest STERIS (STE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STERIS (STE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover STE stock data and trends